Progesterone stimulates production and secretion of MUC1 epithelial mucin in steroid-responsive breast cancer cell lines

International Journal of Oncology

Volumn 12, Issue 4, 1998, Pages 939-945

  McGuckin, Michael A ^a,b   Quin, Rachel J ^a   Ward, Bruce G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Breast cancer; MUC1; Mucin; Oestrogen; Progesterone

Indexed keywords

ESTROGEN; PROGESTERONE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HORMONE ACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0031916815     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.4.939     Document Type: Article

References (52)

1. Patton S, Gendler SJ and Spieer AP: The epithelial mucin, MUC1, of milk, mammary gland and other tissues (review). Biochim Biophys Acta 1241: 407-423, 1995.
2. Wesseling J, Vandervalk SW, Vos HL, Sonnenberg A and Hilkens J: Episialin (MUC1) overexpression inhibits integrinmediated cell adhesion to extracellular matrix components. J Cell Biol 129: 255-265, 1995.
3. Wesseling J, van der Valk SW and Hilkens J: A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 7: 565-577, 1996.
4. Pemberton L, Taylor-Papadimitriou J and Gendler SJ: Antibodies to the cytoplasmic domain of the MUC1 mucin show conservation throughout mammals. Biochem Biophys Res Commun 185: 167-175, 1992.
5. Zrihan-Licht S, Baruch A, Elroy-Stein O, Keydar I and Wreschner DH: Tyrosinc phosphorylation of the MUC1 breast cancer membrane proteins cytokine receptor-like molecules. FEBS Lett 356: 130-136, 1994.
6. Pandey P, Kharbanda S and Kufe D: Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res 55: 4000-4003, 1995.
7. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N and Barrattboycs SM: MUC-1 epithelial tumor mucin-based immunity and cancer vaccines (Review). Immunol Rev 145: 61-89, 1995.
8. Goydos JS, Elder E, Whiteside TL, Finn OJ and Lotze MT: A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63: 298-304, 1996.
9. Xing PX, Michael M, Apostolopoulos V, Prenzoska J, Marshall C, Bishop J and McKenzie IFC: Phase I study of synthetic muc1 peptides in breast cancer. Int J Oncol 6: 1283-1289, 1995.
10. Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, Park SYL, Watanabe M, Gong JL, Hayes DF, Kufe DW and Nadler LM: Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 2: 1367-1370, 1996.
11. Abe M and Kufe D: Transcriptional regulation of DF3 gene expression in human MCF-7 breast carcinoma cells. J Cell Physiol 143: 226-231, 1990.
12. Guadagni F, Schlom J, Pothen S, Pestka S and Greiner JW: Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon. Cancer Immunol Immunother 26: 222-230, 1988.
13. Tran R, Horan Hand P, Greiner JW, Pestka S and Schlom J: Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons. J Interferon Cytokine Res 8: 75-88, 1988.
14. Abe M and Kufe DW: Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells. Cancer Res 44: 4574-4577, 1984.
15. Williams CJ, Wreschner DH, Tanaka A, Tsarfaty I, Keyder I and Dion AS: Multiple protein forms of the human breast tumorassociated epithelial membrane antigen (EMA) are generated by alternative splicing and induced by hormonal stimulation. Biochem Biophys Res Commun 170: 1331-1338, 1990.
16. Williams CJ, Major PP and Dion AS: Enhanced expression and secretion of an epithelial membrane antigen (MA5) in a human mucinous breast tumor line (BT549). Tumor Biol 11: 145-157, 1990.
17. Bader SA and Harris H: Regulation of epitectin production in a malignant cell line. J Cell Sci 87: 375-381, 1987.
18. Irimura T, McIsaac AM, Carlson DA, Yagita M, Grimm EA, Menter DG, Ota DM and Cleary KR: Soluble factor in normal tissues that stimulates high-molecular-weight sialoglycoprotein production by human carcinoma cells. Cancer Res 50: 3331-3338, 1990.
19. Dohi DF, Sutton RC, Frazier ML, Nakamori S, McIsaac AM and Irimura T: Regulation of sialomucin production in colon carcinoma cells. J Biol Chem 268: 10133-10138, 1993.
20. Hilkens J and Buijs F: Biosynthesis of MAM-6, an epithelial sialomucin. Evidence for involvement of a rare proteolytic cleavage step in the endoplasmic reticulum. J Biol Chem 263: 4215-4222, 1988.
21. Ligtenberg MJ, Kruijshaar L, Buijs F, van Meijer M, Litvinov SV and Hilkens J: Cell-associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem 267: 6171-6177, 1992.
22. Ligtenberg MJ, Vos HL, Gennissen AM and Hilkens J: Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 265: 5573-5578, 1990.
23. Abe M and Kufe D: Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc Natl Acad Sci USA 90: 282-286, 1993.
24. Kovarik A, Peat N, Wilson D, Gendler SJ and Taylor-Papadimitriou J: Analysis of the tissue-specific promoter of the MUC1 gene. J Biol Chem 268: 9917-9926, 1993.
25. Abe M, Siddiqui J and Kufe D: Sequence analysis of the 5′ region of the human DF3 breast carcinoma-associated antigen gene. Biochem Biophys Res Commun 165: 644-649, 1989.
26. Tsarfaty I, Hareuveni M, Horev J, Zaretsky J, Weiss M, Jeltsch JM, Gamier JM, Lathe R, Keydar I and Wreschner DH: Isolation and characterization of an expressed hypervariable gene coding for a breast-cancer-associated antigen. Gene 93: 313-318, 1990.
27. Lancaster CA, Peat N, Duhig T, Wilson D, Taylor-Papadimitriou J and Gendler SJ: Structure and expression of the human polymorphic epithelial mucin gene: an expressed VNTR unit. Biochem Biophys Res Commun 173: 1019-1029, 1990.
28. Damstrup L, Andersen J, Kufe DW, Hayes DF and Poulsen HS: Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor. Ann Oncol 3: 71-77, 1992.
29. Angus B, Napier J, Purvis J, Ellis IO, Hawkins RA, Carpenter F and Home CHW: Survival in breast cancer related to tumour oestrogen receptor status and immunohistochemical staining for NCRC11. J Pathol 149: 301-306, 1986.
30. Ellis IO, Bell J, Todd JM, Williams M, Dowle C, Robins AR, Elston CW, Blarney RW and Baldwin RW: Evaluation of immunoreactivity with monoclonal antibody NCRC11 in breast carcinoma. Br J Cancer 56: 295-299, 1987.
31. Ellis IO, Hinton CP, Macnay J, Elston CW, Robins A, Owainati AARS, Blarney RW, Baldwin RW and Ferry B: Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC11: a new prognostic indicator. BMJ 290: 881-883, 1985.
32. Wright C, Angus B, Napier J, Wetherall M, Udagawa Y, Sainsbury JRC, Johnston S, Carpenter F and Home CHW: Prognostic factors in breast cancer: immunohistochemical staining for SP1 and NCRC11 related to survival, tumour epidermal growth factor receptor and oestrogen receptor status. J Pathol 153: 325-331, 1987.
33. Brandt B, Seitzer D, Jackisch C and Assmann G: Quantitative determination of the tumor marker CA15-3 in breast cancer tissue compartments. J Tumor Marker Oncol 6: 173-182, 1991.
34. Gion M, Mione R, Nascimben O, Valsecchi M, Gatti C, Leon A and Bruscagni G: The tumour associated antigen CA 15.3 in primary breast cancer. Evaluation of 667 cases. Br J Cancer 63: 809-813, 1991.
35. Hilkens J, Bonfrer JMG, Kroezen V, Van Eykeren M, Nooyen W, De Jong-Bakker M and Bruning PF: Comparison of circulating MAM-6 and CEA levels and correlation with the estrogen receptor in patients with breast cancer. Int J Cancer 39: 431-435, 1987.
36. Rye PD, Bell SC and Walker RA: Immunohistochemical expression of tumour-associated glycoprotein and polymorphic epithelial mucin in the human endometrium during the menstrual cycle. J Reprod Fertil Suppl 97: 551-556, 1993.
37. Hey NA, Graham RA, Seif MW and Aplin JD: The polymorphic epithelial mucin MUC1 in human endometrium is regulated with maximal expression in the implantation phase. J Clin Endocrinol Metab 78: 337-342, 1994.
38. Wakeling AE and Bowler J: ICI 182,780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol 43: 173-177, 1992.
39. Soule HD, Vazquez J, Long A, Albert S and Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1416, 1973.
40. Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ and Joyce MJ: Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 38: 3352-3364, 1978.
41. Aakvaag A, Utaaker E, Thorsen T, Lea OA and Lahooti H: Growth control of human mammary cancer cells (MCF-7 cells) in culture: effect of estradiol and growth factors in serum-containing medium. Cancer Res 50: 7806-7810, 1990.
42. Harlow E and Lane D: Antibodies: A Laboratory Manual. Cold Spring Harbor, Cold Spring Harbor Laboratory, 1988.
43. Layton GT, Xing PX, McKenzie IFC, Bishop JF and McGuckin MA: Cancer-associated serum antigen (CASA) and ovarian serum antigen (OSA): two new tumor marker kits for detecting carcinoma-associated mucins. J Tumor Marker Oncol 6: 9-17, 1991.
44. McGuckin MA, Hurst TG and Ward BG: Heterogeneity in production, secretion and glycosylation of MUC1 epithelial mucin by primary cultures of ovarian carcinoma. Int J Cancer 63: 412-418, 1995.
45. Xing PX, Tjandra JJ, Stacker SA, Teh JG, Thompson CH, McLaughlin PJ and McKenzie IFC: Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol Cell Biol 67: 183-195, 1989.
46. Xing PX, Reynolds K, Tjandra JJ, Tang XL and McKenzie IF: Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies. Cancer Res 50: 89-96, 1990.
47. Woods LK, Morgan RT, Quinn LA, Moore GE, Semple TU and Stedman KE: Comparison of four new cell lines from patients with adenocarcinoma of the ovary. Cancer Res 39: 4449-4459, 1979.
48. Musgrove EA and Sutherland RL: Steroids, growth factors and cell cycle controls in breast cancer. In: Regulatory Mechanisms in Breast Cancer. Lippman M and Dickson R (eds.) Kluwer Academic Publishers, Boston, pp305-331, 1991.
49. Martin MB, Saceda M and Lindsey RK: Estrogen and progesterone receptors. In: Regulatory Mechanisms in Breast Cancer. Lippman M and Dickson R (eds.) Boston, Kluwer Academic Publishers, pp273-288, 1991.
50. Zotter S, Hageman PC, Lossnitzer A, Mooi WJ and Hilgers J: Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 11-12: 55-101, 1988.
51. Parry G, Li J, Stubbs J, Bissell MJ, Schmidhauser C, Spicer AP and Gendler SJ: Studies of Muc-1 mucin expression and polarity in the mouse mammary gland demonstrate developmental regulation of Muc-1 glycosylation and establish the hormonal basis for mRNA expression. J Cell Sci 101: 191-199, 1992.
52. Braga VM and Gendler SJ: Modulation of Muc-1 mucin expression in the mouse uterus during the estrus cycle, early pregnancy and placentation. J Cell Sci 105: 397-405, 1993.